Cargando…

Stability of serial platelet and urine protein measurements in patients receiving nusinersen for spinal muscular atrophy

INTRODUCTION/AIMS: Patients undergoing nusinersen treatment for spinal muscular atrophy are subject to measurements of platelet count and urine protein before each injection due to concern for platelet depletion and renal dysfunction according to the prescribing information. These tests may be uncom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagarajan, Eric K., Özütemiz, Can, Rubin, Nathan, Nascene, David R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Clinical Research Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321971/ https://www.ncbi.nlm.nih.gov/pubmed/35466424 http://dx.doi.org/10.1002/mus.27564

Ejemplares similares

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021)

Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy
por: Orbach, Rotem, et al.
Publicado: (2022)

Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy
por: Li, Qing
Publicado: (2020)

Nusinersen and Spinal Muscular Atrophies: Where are we in 2020?
por: Khadilkar, Satish V., et al.
Publicado: (2020)

Nusinersen improves walking distance and reduces fatigue in later‐onset spinal muscular atrophy
por: Montes, Jacqueline, et al.
Publicado: (2019)

Symptomatic intracranial hypertension in an adult patient with spinal muscular atrophy and arachnoid cysts receiving nusinersen
por: Machetanz, Gerrit, et al.
Publicado: (2023)

Fatigue in adults with spinal muscular atrophy under treatment with nusinersen
por: Kizina, K., et al.
Publicado: (2020)

Parents’ perspectives on nusinersen treatment for children with spinal muscular atrophy
por: van Kruijsbergen, Mette, et al.
Publicado: (2021)

Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study
por: Acsadi, Gyula, et al.
Publicado: (2021)

Nusinersen: A Review in 5q Spinal Muscular Atrophy
por: Hoy, Sheridan M.
Publicado: (2021)

Scoliosis in Spinal Muscular Atrophy Type 1 in the Nusinersen Era
por: Al Amrani, Fatima, et al.
Publicado: (2022)

Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
por: Nuzzo, Tommaso, et al.
Publicado: (2023)

Nusinersen in type 0 spinal muscular atrophy: should we treat?
por: Tiberi, Eloisa, et al.
Publicado: (2020)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
por: Pera, Maria Carmela, et al.
Publicado: (2021)

Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy
por: Hoy, Sheridan M.
Publicado: (2021)

History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy
por: Qiu, Jiaying, et al.
Publicado: (2022)

Real-world Adherence to Nusinersen in Adults with Spinal Muscular Atrophy in the US: A Multi-site Chart Review Study
por: Elman, Lauren, et al.
Publicado: (2022)

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy
por: Cordts, Isabell, et al.
Publicado: (2020)

Exploratory evaluation of an eye-tracking system in patients with advanced spinal muscular atrophy type I receiving nusinersen
por: Yae, Yukako, et al.
Publicado: (2022)

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience
por: Haché, Manon, et al.
Publicado: (2016)

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
por: Stolte, Benjamin, et al.
Publicado: (2018)

Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
por: Thokala, Praveen, et al.
Publicado: (2020)

Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients
por: Osmanovic, Alma, et al.
Publicado: (2021)

Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
por: Osmanovic, Alma, et al.
Publicado: (2021)

Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy
por: Freigang, Maren, et al.
Publicado: (2021)

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
por: Elsheikh, Bakri, et al.
Publicado: (2021)

Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen
por: Kariyawasam, Didu, et al.
Publicado: (2021)

Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy
por: Errico, Francesco, et al.
Publicado: (2022)

Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen
por: Weststrate, Harriet, et al.
Publicado: (2022)

Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy
por: Beaudin, Marie, et al.
Publicado: (2023)

Intrathecal administration of nusinersen for spinal muscular atrophy: report of three cases with severe spinal deformity
por: Nakao, Sayo, et al.
Publicado: (2020)

Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function †
por: Dunaway Young, Sally, et al.
Publicado: (2023)

Is cerebrospinal fluid amyloid‐β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?
por: Introna, Alessandro, et al.
Publicado: (2021)

Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy
por: Osmanovic, Alma, et al.
Publicado: (2020)

Limited Assessment of Respiratory Muscle Response to Nusinersen Treatment in Infants with Spinal Muscular Atrophy
por: Chacko, Archana, et al.
Publicado: (2020)

Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen
por: Arnold, W David, et al.
Publicado: (2021)

Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I
por: Mirea, Andrada, et al.
Publicado: (2021)

Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment
por: Freigang, Maren, et al.
Publicado: (2021)

Quality of Life Outcomes According to Differential Nusinersen Exposure in Pediatric Spinal Muscular Atrophy
por: Weaver, Meaghann S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3c5doil3cfnf1c6i9cip0qb5td